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TNFα-stimulated gene-6 (TSG6), a 30-kDa protein generated by acti-
vatedmacrophages, modulates inflammation; however, its mechanism
of action and role in the activation of macrophages are not fully un-
derstood. Herewe observedmarkedly augmented LPS-induced inflam-
matory lung injury and mortality in TSG6−/− mice compared with WT
(TSG6+/+) mice. Treatment of mice with intratracheal instillation of
TSG6 prevented LPS-induced lung injury and neutrophil sequestration,
and increased survival in mice. We found that TSG6 inhibited the
association of TLR4withMyD88, thereby suppressing NF-κB activation.
TSG6 also prevented the expression of proinflammatory proteins (iNOS,
IL-6, TNFα, IL-1β, and CXCL1) while increasing the expression of anti-
inflammatory proteins (CD206, Chi3l3, IL-4, and IL-10) in macrophages.
This shift was associatedwith suppressed activation of proinflammatory
transcription factors STAT1 and STAT3. In addition, we observed
that LPS itself up-regulated the expression of TSG6 in TSG6+/+
mice, suggesting an autocrine role for TSG6 in transitioning macro-
phages. Thus, TSG6 functions by converting macrophages from a
proinflammatory to an anti-inflammatory phenotype secondary to
suppression of TLR4/NF-κB signaling and STAT1 and STAT3 activation.
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acute lung injury
TNFα-stimulated gene-6 (TSG6) is a 30-kDa hyaluronan(HA)-binding protein produced by monocytes/macrophages,
mesenchymal stem cells (MSCs), and fibroblasts in inflammatory
diseases (1–4). However, there appears to be little constitutive
expression of TSG6 (3). TSG6 is synthesized in response to
proinflammatory mediators, including lipopolysaccharide (LPS),
TNFα, and IL-1β (3–5). TSG6 is composed of an HA-binding
LINK domain and a CUB (complement protein subcomponents
C1r/C1s, urchin embryonic growth factor, and bone morphoge-
netic protein) domain (3, 4) To date, only the HA-binding pro-
tein CD44 has been shown to function as a TSG6 receptor (6).
TSG6 has a potent but poorly understood function in suppressing
inflammation through inhibition of neutrophil migration and pro-
duction of proinflammatory cytokines (7, 8). This effect of TSG6 has
been demonstrated in several models. TSG6 was shown to prevent
inflammation and tissue injury in rodent models of arthritis (9),
myocardial infarction (10), corneal injury (11), and peritonitis (12).
Both IL-1β and TNFα induced the synthesis of TSG6 in MSCs,
monocytes/macrophages, and fibroblasts (2, 4, 5). Administration of
humanMSCs in mice prevented endotoxin (LPS)-induced acute lung
injury (ALI), and, importantly, this effect was abrogated using cells
pretreated with TSG6-siRNA to suppress TSG6 expression (13).
TSG6 also delayed the onset of autoimmune diabetes by suppressing
the activation of T cells and antigen-presenting cells (14), further
supporting its role in dampening the adaptive immune response.
In the present study, we addressed the role of TSG6 in ALI, an
acute inflammatory disease that injures the lung’s vascular barrier,
resulting in severe protein-rich pulmonary edema and hypoxemia,
associated with ∼50% mortality (15). There is a profound release
of proinflammatory cytotoxic mediators from activated alveolar
macrophages and other inflammatory cells sequestered in lungs (15).
Macrophages in ALI are activated through the sensing of pathogen-
associated molecular patterns (PAMPs) and damage-associated
molecular patterns (DAMPs) via Toll-like receptors (TLRs). On
binding of LPS to TLR4, macrophages produce proinflammatory
cytokines, such as IFNγ, TNFα, and IL-1β, which signal the re-
cruitment of neutrophils and lymphocytes at the site of infection and
aid in the clearance of pathogens (16). However, macrophages also
display marked plasticity and functional heterogeneity depending on
such factors as their niche, interaction with other cells (e.g., endo-
thelial cells), and cytokines to which they are exposed (17, 18).
Macrophages are classified as classically activated macrophages,
or M1 type, and alternatively activated macrophages, or M2 type
(17, 18). Within this classification, macrophages are polarized to the
M1 in response to LPS and other mediators, such as IFNγ, whereas
M2 macrophages are generated in response to IL-4, IL-10, and
glucocorticoids (18–20). Each type is characterized by distinct mo-
lecular signatures, such as iNOS, IL-12, IL-6, TNFα, and STAT1 for
M1 and arginase-1, chitinase-3-like-3 (Chi3l3), IL-10, IL-4, and
STAT6 for M2 (17–20). However, recent transcription data indicate
that macrophages exhibit a far more complex range of phenotypes
than are accounted for by the M1/M2 classification scheme (17–20).
The basis for macrophage polarization in vivo is not clear, but
NF-κB activation downstream of TLR4 and up-regulation of spe-
cific cytokines and transcription factors, such as STAT6, appear to
be important in mediating macrophage plasticity (20–24).
We examined the role of TSG6, a macrophage releasate, in
mediating the phenotypic shift of macrophages and in counter-
acting LPS-induced ALI in mice. We found that TSG6 is crucial in
mediating the transition of macrophages and thereby inhibiting the
inflammatory feed-forward cascade activated by LPS. We show that
the TSG6-mediated reprogramming of macrophages is essential
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for the resolution of ALI. The expression of anti-inflammatory
macrophage signatures (arginase-1 and Chi3l3) was abrogated in
TSG6−/− mice, whereas the expression of proinflammatory
transcription factors STAT1 and STAT3 was enhanced. TSG6
expression in macrophages was itself increased in response to LPS,
resulting in a cell population displaying a distinct anti-inflammatory
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Fig. 1. TSG6 deletion in mice (TSG6−/−) augments LPS-induced inflammatory lung injury. (A and B) WT (TSG6+/+) and TSG6−/−mice were challenged with LPS
(10 mg/kg i.p.). (A) Lungs obtained at 0, 24 h, and 48 h after LPS challenge were used to measure MPO activity in lungs. (B) After LPS challenge, lung vascular
permeability (uptake of EBA) was assessed. n = 4 mice per time point. *P < 0.05, WT vs. TSG6−/−. (C) Survival of age- and weight-matched WT and TSG6−/−
mice monitored after challenge with a lethal dose of LPS (20 mg/kg i.p.). TSG6−/− mice showed the highest mortality within 20 h after LPS injection
compared with WT mice. n = 10 per group. *P < 0.001, WT vs. TSG6−/−. (D) Survival of TSG6−/− mice challenged with LPS (20 mg/kg, i.p.) with and without
simultaneous i.t. instillation of TSG6 (5 μg/mouse). TSG6 instillation rescued the high mortality seen in the TSG6−/− mice, increasing survival by 60%
compared with untreated controls. n = 8 mice per group. *P < 0.001. (E and F) WT mice were simultaneously challenged with LPS (10 mg/kg, i.p.) and saline
(i.t) or TSG6 (5 μg/mouse, i.t.). (E ) At 0 and 24 h after LPS/saline or LPS/TSG6 administration, mice were used for lung EBA permeability measurements as
above. Mice treated with TSG6 showed significantly reduced lung vascular permeability compared with untreated control mice. n = 5 mice per group; *P <
0.05, LPS vs. LPS + TSG6. (F) At 0 and 24 h after LPS/saline or LPS/TSG6 administration, lungs were used to measure MPO activity, expressed as change in ab-
sorbance (ΔA). MPO activity was significantly reduced in lungs of TSG6-treated mice compared with saline-treated control mice. n = 4 mice per group. *P < 0.05,
LPS vs. LPS + TSG6. (G) Survival in WT mice, monitored for 72 h after a lethal dose of LPS (20 mg/kg i.p.) alone or in combination with TSG6 (5 μg/mouse) given i.t.
either concomitantly with or 6 h after LPS challenge. n = 10 per group. *P < 0.001, LPS vs. LPS + TSG6; *P < 0.03, LPS vs. LPS + TSG6 post-LPS.
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Fig. 2. TSG6 inhibits the interaction of TLR4 with MyD88 and prevents NF-κB activation. (A) Macrophages cultured from bone marrow of WT mice were
challenged with LPS (1 μg/mL) alone or TSG6 (0.1 μg/mL) plus LPS (1 μg/mL) together for 0 and 15 min. Cells were fixed, permeabilized, and stained, and
images were acquired by confocal microscopy. Green, TLR4; red, MyD88; blue, DAPI. Strong colocalization of TLR4 with MyD88 was seen after LPS challenge,
and this response was prevented by rTSG6. (Scale bar: 20 μm.) (B) WT macrophages cultured from bone marrow were treated with LPS (1 μg/mL) alone or with
rTSG6 (0.1 μg/mL) plus LPS (1 μg/mL) for different times. They were then lysed and immunoprecipitated with anti-TLR4 polyclonal antibody (pAb). Immu-
noprecipitated samples were blotted with anti-MyD88 or anti-TSG6 pAb, and blots were reprobed with anti-TLR4 pAb. A strong interaction of MyD88 with
TLR4 was observed at 15 min after LPS treatment, which was abolished by rTSG6. (C) The cell lysates were immunoblotted with anti–phos-Ser177/181-IKKβ
pAb. Quantified results are shown as ratio of phosphorylated to total protein (Bottom). rTSG6 treatment decreased LPS-induced phosphorylation of IKKβ.
*P < 0.05, LPS vs. LPS + TSG6.
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phenotype. This indicates that TSG6 plays a vital role in the res-
olution of inflammatory lung injury in vivo by converting macro-
phages to the anti-inflammatory phenotype, and furthermore, that
TSG6 expression is a strong indicator of the innate immune func-
tion of macrophages.
Results
TSG6 Deletion (TSG6−/−) in Mice Augments Lung Vascular Injury,
Neutrophil Sequestration, and Mortality Induced by LPS. We chal-
lenged TSG6−/− mice with 20 mg/kg LPS i.p. and measured lung
vascular permeability (an index of vascular injury) using Evans blue
dye conjugated with albumin (EBA) tracer and neutrophil se-
questration by assaying lung tissue myeloperoxidase (MPO) con-
tent. TSG6−/− mice showed a higher basal MPO level compared
with WT mice, although the basal vascular permeability value was
not significantly greater than that in WT mice (Fig. 1 A and B).
However, at 24 h after LPS challenge, TSG6−/−mice demonstrated
significantly greater lung vascular injury and neutrophil accumula-
tion compared with WT mice (Fig. 1 A and B). In contrast, at 48 h
after LPS challenge, lung vascular injury and neutrophil seques-
tration both recovered to basal values in WT mice, but persisted in
TSG6−/− mice (Fig. 1 A and B). We also observed 100% mortality
in TSG6−/−mice (generated on a BALB/c background) within 20 h
of the LPS challenge, whereas all WTmice of the same background
survived (Fig. 1C), consistent with the survival results reported in
other studies in mice of the BALB/c strain given LPS (25).
Next, to determine whether exogenous administration of TSG6
was itself protective, we evaluated the effects of intratracheal (i.t.)
instillation of recombinant (r) TSG6. We observed that TSG6−/−
mice treated with rTSG6 before LPS challenge showed 60% sur-
vival, compared with no survival of TSG6−/− mice (Fig. 1D). Thus,
TSG6 administration significantly reduced the mortality seen in
TSG6−/− mice.
TSG6 Treatment Prevents LPS-Induced Lung Vascular Injury, Neutrophil
Infiltration, and Mortality. We challenged WT mice with i.p. LPS
and simultaneously instilled rTSG6 i.t., and then at 24 h post-LPS
challenge assessed lung vascular injury and neutrophil uptake as
above. rTSG6 significantly reduced LPS-induced lung vascular
injury and neutrophil sequestration (Fig. 1 E and F). To investigate
the prophylactic vs. therapeutic effects of rTSG6, we divided the
mice into three groups. Group I was challenged with i.p. LPS
alone, group 2 received concomitant i.p. LPS and i.t. rTSG6, and
group 3 received i.t. rTSG6 at 6 h post-LPS challenge, when the
mice had a high probability of dying. In group 1 (LPS alone), all
mice died within 48 h of the LPS challenge (Fig. 1G). Group 2
(concomitant rTSG6 and LPS) showed 80% survival, and, sur-
prisingly, group 3 mice (rTSG6 at 6 h post-LPS) showed 50%
survival (Fig. 1G).
TSG6 Prevents the Interaction of TLR4 with MyD88 and NF-κB Activation.
We next determined whether rTSG6 interfered with TLR4 sig-
naling, which induces NF-κB activation via MyD88-dependent
and MyD88-independent pathways (26). In control bone marrow-
derived macrophages, LPS induced IκB kinase β (IKKβ) phosphor-
ylation within 5 min; however, a strong TLR4–MyD88 association
was observed only within 15 min (Fig. 2 A–C). rTSG6 suppressed
IKKβ activation and inhibited the association of MyD88 with TLR4
(Fig. 2 A–C); thus, TSG6 functions by preventing MyD88-dependent
NF-κB activation.
TSG6 Reprograms Macrophage Phenotype in Vivo. To investigate
mechanisms of TSG6 inhibition of LPS-induced ALI, we injected
mice with i.p. LPS (10 mg/kg) alone or concomitantly with i.t.
rTSG6 (5 μg/mouse). At 6 h and 24 h after LPS, we measured
concentrations of proinflammatory cytokines IL-6, TNFα, IFNγ,
and IL-12p70 and anti-inflammatory cytokines IL-10 and IL-4
in bronchoalveolar lavage (BAL) fluid. TSG6 treatment significantly
reduced the generation of IL-6, IFNγ, TNFα, and IL-12p70 while
increasing the generation of IL-10 and IL-4 (Fig. 3 A and B). In
other experiments, we obtained CD11b+ cells (alveolar macrophages)
from BAL fluid of mice at 24 h post-LPS. TSG6 treatment of these
mice suppressed the LPS-mediated induction of proinflammatory
transcripts iNOS, IL-6, TNFα, IL-1β, and CXCL1 while augmenting
anti-inflammatory markers CD206 and Chi3l3 in the alveolar
macrophages (Fig. 3C).
We also isolated CD11b+macrophages from digested lungs at 24 h
after challenging mice with either i.p. LPS or i.p. LPS plus TSG6, and
assessed the expression of proinflammatory and anti-inflammatory
proteins by Western blot analysis and ELISA. rTSG6 suppressed the
phosphorylation of the proinflammatory transcription factors STAT1
and STAT3, as well as the expression of IL-1β in these cells (Fig. 4A).
Interestingly, the CD11b+ cells obtained from the rTSG6-treated
mice showed increased expression of arginase-1 and Chi3l3, in-
dicative of the anti-inflammatory phenotype shift (Fig. 4A).
We next placed the CD11b+ cells in culture for 3 d, and then
used the culture supernatants for cytokine measurements. We ob-
served that CD11b+ macrophages obtained from the mice treated
with TSG6 exhibited reduced production of TNFα, IL-6, IFNγ, and
IL-12p70 and increased production of IL-10 and IL-4 (Fig. 4B).
In these studies, we also determined whether LPS itself could
could up-regulate TSG6 expression. We observed that LPS given
i.p. induced the TSG6 expression in the lungs of WT mice, but not
of TSG6−/−mice (Fig. 4C). LPS also induced phosphorylation of
the proinflammatory transcription factors STAT1 and STAT3 at
6 h of the LPS challenge in TSG6+/+ mice, followed by a return to
baseline at 24 h (Fig. 4C). In contrast, LPS induced sustained
phosphorylation of STAT1 and STAT3 in TSG6−/−mice (Fig. 4C),
indicating that TSG6 regulates STAT1 and STAT3 activities. Im-
portantly, LPS induced a sustained expression of IL-1β in TSG6−/−
mice, but not in TSG6+/+mice (Fig. 4C), suggesting the crucial role
of TSG6 in dampening inflammation. We also observed that ex-
pression of anti-inflammatory proteins arginase-1 and Chi3l3 was
increased in TSG6+/+ mice post-LPS, whereas their expression was
defective in TSG6−/− mice (Fig. 4C).
Discussion
TSG6 was first described as an anti-inflammatory factor released
by TNFα-treated fibroblasts (27, 28). IL-1β and TNFα have been
shown to induce TSG6 expression in multiple cell types (2–5, 29).
Human and murine TSG6 proteins are ∼94% identical (4).
Transgenic mice overexpressing TSG6 were resistant to collagen-
induced arthritis (CIA) (9), whereas inactivation of the TSG6
gene enhanced inflammation and increased the susceptibility to
arthritis (30). Intravenous administration of MSCs in mice also
prevented endotoxin-mediated ALI, apparently by reducing the
expression of proinflammatory cytokines and neutrophil seques-
tration in lungs (13); however, siRNA-mediated suppression of
TSG6 expression in MSCs prevented these protective effects, in-
dicating the involvement of TSG6 in this protection. In another
study, TSG6 prevented zymosan-induced peritonitis secondary to
reduced TLR2-mediated nuclear translocation of NF-κB (12).
TSG6 also has been shown to reduce inflammation by inhibiting
NF-κB signaling in a model of sterile injury of the cornea (11, 31).
Although the anti-inflammatory effects of TSG6 have been well
described (1, 2, 7–14, 29, 32), how it modulates inflammation has
not been addressed until now. Here, in studies performed in a
model of LPS-induced inflammatory lung injury that simulates
ALI, we have demonstrated that (i) TSG6−/− mice exhibit mark-
edly augmented lung vascular injury and neutrophil sequestration
and mortality, which is reversed by i.t. TSG6 instillation; (ii) i.t.
TSG6 instillation even at 6 h after the onset of lung injury reduces
mortality by 50% from the 100% mortality seen in untreated
control mice; and (iii) TSG6 functions by interfering with TLR4–
MyD88 interaction in macrophages to inhibit NF-κB and STAT1
and STAT3 activation, and thereby promote the transition of
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anti- inflammatory macrophages. We also observed that LPS itself
up-regulated the expression of TSG6 in lung as reported previ-
ously (3–5, 29), consistent with its role as an autocrine mediator
resolving inflammatory injury.
NF-κB activation is a known driver of inflammatory signaling
(33). Our results show that the rTSG6-mediated suppression of
MyD88-dependent NF-κB activation is essential for reprogramming
macrophages. Of note, the LPS-induced IKKβ phosphorylation was
observed in 5 min, but a strong association of TLR4 and MyD88
was not seen until 15 min. Although the reason for this discrepancy
is not clear, the early IKKβ phosphorylation could have been me-
diated by MyD88-independent pathways (26). In response to
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Fig. 3. TSG6 induces expression of anti-inflammatory factors while suppressing proinflammatory factors in alveolar macrophages. (A and B) Concentrations
of proinflammatory cytokines (IL-6, TNFα, IFNγ, and IL12p70) and anti-inflammatory cytokines (IL-10 and IL-4) were measured in BAL fluid of mice challenged
with either i.p. LPS (10 mg/kg) and i.t. saline or i.p. LPS (10 mg/kg) and i.t. TSG6 (5 μg) for 6 h (A) or 24 h (B). TSG6 significantly decreased the production of IL-6,
TNFα, IFNγ, and IL-12p70 while increasing the production of IL-10 and IL-4. n = 4 mice per group. *P < 0.05. (C) Quantification of transcript expression of iNOS,
IL-6, IL-1β, TNFα, CXCL1, Chi3l3, and CD206 by qPCR in CD11b+ alveolar macrophages from BAL fluid of mice challenged with either i.p. LPS (10 mg/kg) for 24 h
or i.p. LPS (10 mg/kg) and i.t. TSG6 (5 μg) for 24 h. *P < 0.05, LPS vs. LPS + TSG6.
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Fig. 4. TSG6 induces suppression of proinflammatory proteins and up-regulation of anti- inflammatory proteins in CD11b+ lung macrophages. (A) Immu-
noblots showing expression of proinflammatory proteins (STAT1, STAT3, and IL-1β) and anti-inflammatory proteins (arginase-1 and Chi3l3) in purified CD11b+
macrophages obtained from lungs of mice challenged with LPS for 24 h. Results are representative of two separate experiments. (B) Concentrations of
proinflammatory cytokines (IL-6, TNFα, IFNγ, and IL-12p70) and anti-inflammatory cytokines (IL-10 and IL-4) in cultured supernatants of CD11b+ lung mac-
rophages. *P < 0.05, LPS vs. LPS + TSG6. (C) Immunoblots showing expression of TSG6 and proinflammatory and anti-inflammatory proteins (pSTAT1, pSTAT3,
IL-1β, Chi3l3, and arginase-1) in lung lysates of LPS-challenged WT and TSG6−/− mice. Results are representative of two separate experiments.
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rTSG6, the macrophages shifted from generating proinflammatory
cytokines TNFα, IL-1β, IL-6, and IL-12p70 to generating a distinct
anti-inflammatory phenotype. NF-κB is normally maintained in an
inactive state in the cytoplasm by inhibitory proteins, such as IκB
(33). Macrophage polarization to the anti-inflammatory phenotype
requires the formation of inactive dimers of the p50 subunit of NF-
κB, resulting in suppression of NF-κB–driven macrophage polari-
zation (22). We observed that rTSG6 prevents the interaction of
TLR4 with MyD88, a requirement for the activation of NF-κB
signaling (33), and that this in turn induces the shift toward anti-
inflammatory macrophages. Similar results were seen in a model of
zymosan-induced peritonitis in which TSG6 prevented the inter-
action of TLR2 with MyD88 and thus inhibited the activation of
NF-κB (12).
Macrophage polarization is a central feature of inflammatory
disease progression, such as in ALI (17, 18). In lungs, resident al-
veolar macrophages are the first line of defense against airway
pathogens. They orchestrate the inflammatory response through
activation of pattern recognition receptors that initiate both in-
flammatory and resolution pathways (17, 18). The phenotype of
anti-inflammatory macrophages is characterized by the proteins
arginase-1, Chi3l3, pSTAT6, IL-4, and IL-10, whereas proin-
flammatory macrophages express iNOS, pSTAT1, pSTAT3, TNFα,
IL-6, IFNγ, IL-12p70, and IL-1β (17–21, 23, 24). We have shown
that TSG6 reprograms macrophages to the anti-inflammatory phe-
notype, which resolves ALI.
Mice genetically deficient in TSG6 (TSG6−/−) exhibited far
greater mortality than controls owing to the inability to reprogram
macrophages, and thus to resolve ALI. Because TSG6 is released
in the inflammatory milieu (3, 29), our finding that TSG6 induces
the phenotype switch in macrophages suggests the therapeutic
potential of TSG6 in sepsis-induced ALI. Of special note is that
the effective dose of TSG6 administered i.t. was only 5 μg, or one-
tenth the dose required for efficacy with i.v. administration in
several mouse models of inflammation (8–13, 32).
Materials and Methods
Mouse Experiments. All mice were housed at the University of Illinois Animal
Care Facility in accordance with institutional guidelines and guidelines of
the National Institutes of Health. Veterinary care of the mice and the related
animal experiments was approved by the University of Illinois Animal Resources
Center. The TSG6 knockout mice originally generated on a BALB/c background
(30) were obtained from Jackson Laboratory. Age-matched TSG6+/+ and TSG6−/−
littermates were used for all experiments.
Endotoxin-Induced ALI and i.t. rTSG6 Instillation. Age- and weight-matched
TSG6+/+ and TSG6−/− mice received a single i.p. dose of LPS (10 mg/kg body
weight; Escherichia coli strain 0111:B4; Sigma-Aldrich). The mice were given a
single 5-μg dose of rTSG6 (2104-TS-050; R&D Systems) by noninvasive i.t. in-
stillation. For i.t. instillation, the mice were anesthetized by ketamine/xylazine
(45 mg/kg and 8 mg/kg, respectively) and were suspended on a flat board and
placed in a semirecumbent position with the ventral surface and rostrum facing
up. Using a curved blade forceps, the tongue was gently and partially retracted
rostrally, and 50 μL containing 5 μg of rTSG6 was placed in the trachea. Saline
(50 μL) alone was similarly administered to the control mice. For survival
studies, mice injected i.p. with 20 mg/kg LPS were monitored four times daily
for up to 3 d.
MPO Assay. MPO activity in lung tissue was measured as described previously
(34). The lungs were homogenized in 1 mL of PBS with 0.5% hexadecyl-
trimethylammonium bromide. The homogenates were sonicated, centrifuged
at 40,000 × g for 20 min, and run through two freeze-thaw cycles. The samples
were homogenized and centrifuged a second time. The supernatant was then
collected and mixed 1/30 (vol/vol) with assay buffer (0.2 mg/mL o-dianisidine
hydrochloride and 0.0005% H2O2). The change in absorbance was measured at
460 nm for 3 min, and MPO activity was calculated as the change in absor-
bance over time.
Measurement of Lung Vascular Permeability. Lung vascular leak was measured
using EBA as described previously (35). Mice anesthetized with 2.5% (vol/vol)
isoflurane in room air were injected retro-orbitally with 150 μL of EBA (30mg/kg).
At 30 min after EBA injection, animals were killed, and lung tissue was harvested
for EBA measurement.
Bone Marrow-Derived Macrophage Cultures. For the isolation of bone marrow
cells, femur cavities fromWTmice (C57bl/6) were flushed, the cells were plated
at approximately 2 × 106 cells/mL, and incubated in DMEM supplemented with
10% (vol/vol) FBS, 1% (vol/vol) streptomycin/penicillin, and 10% (vol/vol) L929-
conditioned media for 1 wk. Cells were used for experiments at day 7
of culture.
Immunoprecipitation. Bone marrow-derived macrophages were stimulated with
LPS (1 μg/mL) alone or in combination with TSG6 (0.1 μg/mL) for 0, 5, 15, and
30 min. After this treatment, cells were lysed in lysis buffer (final concentration:
10 mM Tris·HCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 1 mM
sodium vanadate, 1% Triton X100, and 0.5% Nonidet P-40) supplemented with
protease inhibitor mixture. The cell lysate was cleared of cellular debris by
centrifuging at 12,000 × g for 10 min. The clear supernatant collected was
subjected to immunoprecipitation. Each sample was incubated overnight with
TLR4 antibody (1 μg/mL) at 4 °C on a rotating platform. Next day, protein A/G
beads were added to the sample and incubated for 1 h at 4 °C. Immunopre-
cipitated samples were washed three times and used for immunoblotting.
Immunostaining. Bone marrow-derived macrophages from mice grown on
coverslips were stimulated with LPS (1 μg/mL) alone or in combination with
TSG6 (0.1 μg/mL) for 0 and 15 min. After this treatment, cells were fixed and
used for immunostaining (36).
Collection of BAL Fluid and Cells. For collection of BAL fluid, the upper part of
the trachea was cannulated and then lavaged three times with 0.8 mL of PBS
supplemented with 0.4 mM EDTA and protease inhibitor mixture. The fluid
recovery rate typically exceeds 90%. The lavage samples from each mouse
were kept on ice. BAL fluid was centrifuged at 700 × g for 5 min at 4 °C. The
collected supernatant was then used for cytokine assays.
Immunoblotting. Cells were lysed in lysis buffer (50 mM Tris·HCl pH 7.5, 150 mM
NaCl, 1mMEGTA, 1%TritonX-100, 0.25% sodiumdeoxycholate, 0.1%SDS, and
protease inhibitormixture).Mouse lungswere homogenized in lysis buffer (35).
Cell lysates or mouse lung homogenates were centrifuged at 14,000 × g at 4 °C
for 10 min, and cleared supernatant was used for immunoblot analysis. The
protein lysates were resolved by SDS/PAGE on a 4–15% gradient separating gel
under reducing conditions and transferred to PVDF membrane. The mem-
brane was blocked with 3% (wt/vol) BSA in TBST (10 mM Tris·HCl pH 7.5, 150 nM
NaCl, and 0.05% Tween-20) for 1 h at room temperature. The membranes were
then probed with the indicated primary antibody (diluted in blocking buffer)
overnight at 4 °C. Next, membranes were washed three times and then incu-
bated with an appropriate HRP-conjugated secondary antibody. Protein bands
were detected by enhanced chemiluminescence. The following antibodies were
used for immunoblotting: TSG6 (MAB-2104; R&D Systems), TLR4 (sc-30002; Santa
Cruz Biotechnology), MyD88 (sc-8196; Santa Cruz Biotechnology), phosphor-
STAT1Y701 (612233; BD Biosciences), pSTAT3Y705 (51-9002097; BD Biosciences),
Chi3l3 (AF2446; R&D Systems), Arginase-1 (610708; BD Biosciences), IL-1β
(AF401; R&D Systems), phospho-IKKα/β (2697; Cell Signaling Technology), total
IKK (2684; Cell Signaling Technology), and anti–β-actin (A5316, mouse mono-
clonal; Sigma-Aldrich). Band intensity was determined by densitometry with
the aid of ImageJ software.
Cytokine ELISA. Cytokines were measured in BAL fluid and supernatants of
cultured macrophages with commercially available ELISA kits (eBioscience)
according to the manufacturer’s instructions.
Isolation of CD11b+ Alveolar Macrophages. The CD11b+ cells were isolated from
total BAL fluid by incubation with CD11b+ magnetic beads (Miltenyi Biotec)
(37) according to the manufacturer’s instructions. For isolation of CD11b+ cells
from the lungs, the harvested lungs were minced into small pieces and then
incubated in DMEM with 1% penicillin-streptomycin for 30 min at 37 °C and
5% (vol/vol) CO2 in the presence of 1 mg/mL collagenase A (70499828; Roche).
After incubation, the minced pieces of lungs were passed through 16G and
18G needles, and the resulting suspension was passed through a 70-μm cell
strainer and then washed with complete DMEM. The cells were centrifuged at
200 × g for 3 min, incubated for 20 min at 4 °C with CD11b magnetic beads,
and finally applied and eluted from MS columns (Miltenyi Biotec) for the
positive selection of CD11b+ cells.
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RNA Extraction and qRT-PCR. Total RNA isolated from CD11b+ cells was
reverse-transcribed with random hexamers and MultiScribe reverse tran-
scriptase (Applied Biosystems). The cDNA thus obtained was mixed with
SYBR Green PCR Master Mix (Applied Biosystems) and gene-specific primers
for PCR. An ABI Prism 7000 was used for quantitative PCR analysis. Cyclo-
philin expression served as an internal control. The following mouse primers
were used: iNOS (forward, 5′-AGTCTCAGACATGGCTTGCCCCT-3′; reverse, 5′-
GCTGCGGGGAGCCATTTTGGT-3′), IL-6 (forward, 5′-TCCAGTTGCCTTCTTGG-
GACTG-3′; reverse, 5′-AGCCTCCGACTTGTGAAGTGGT-3′), TNFα (forward, 5′-
GACCCTCACACTCAGATCATCT-3′; reverse, 5′-CCTCCACTTGGTGGTTTGCT-3′),
IL-1β (forward, 5′-GAATCTATACCTGTCCTGTG-3′; reverse, 5′-TTATGTCCTGA-
CCACTGTTG-3′), CXCL1 (forward, 5′- CTGGGATTCACCTCAAGAACATC-3′; reverse,
5′-CAGGGTCAAGGCAAGCCTC-3′), Chi3l3 (forward, 5′-AGAAGGGAGTTTCAAAC-
CTGGT-3′; reverse, 5′-GTCTTGCTCATGTGTGTAAGTGA-3′), CD206 (forward,
5′-CCACGGATGACCTGTGCTCGAG-3′; reverse, 5′- ACACCAGAGCCATCCGTCCGA-3′),
and CYP (forward, 5′-CTTGTCCATGGCAAATGCTG-3′; reverse, 5′-GTGATCTTCTTG-
CTGGTCTTGC-3′).
Statistical Analysis. Data were analyzed using the unpaired Student’s t test and
log-rank test. A difference in mean values was considered significant at a
P value <0.05.
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